[HTML][HTML] Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with immunosuppressive T cell phenotype
S Hiltbrunner, L Cords, S Kasser, SN Freiberger…�- Nature�…, 2023 - nature.com
Immune checkpoint inhibitor treatment has the potential to prolong survival in non-small cell
lung cancer (NSCLC), however, some of the patients develop resistance following initial�…
lung cancer (NSCLC), however, some of the patients develop resistance following initial�…
[PDF][PDF] Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with immu-nosuppressive T cell phenotype
SN Freiberger, S Kreutzer…�- Nature�…, 2023 - lungenkrebs-stiftung.ch
Results Patient history We analyzed 14 paired samples from seven patients with stage IV
NSCLC, who initially responded to anti-PD-1 immunotherapy but then developed resistance�…
NSCLC, who initially responded to anti-PD-1 immunotherapy but then developed resistance�…
Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with immunosuppressive T cell phenotype
S Hiltbrunner, L Cords, S Kasser, SN Freiberger…�- Nature�…, 2023 - zora.uzh.ch
Immune checkpoint inhibitor treatment has the potential to prolong survival in non-small cell
lung cancer (NSCLC), however, some of the patients develop resistance following initial�…
lung cancer (NSCLC), however, some of the patients develop resistance following initial�…
Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with immunosuppressive T cell phenotype
S Hiltbrunner, L Cords, S Kasser…�- Nature�…, 2023 - research-collection.ethz.ch
Immune checkpoint inhibitor treatment has the potential to prolong survival in non-small cell
lung cancer (NSCLC), however, some of the patients develop resistance following initial�…
lung cancer (NSCLC), however, some of the patients develop resistance following initial�…
Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with immunosuppressive T cell phenotype
S Hiltbrunner, L Cords, S Kasser…�- Nature�…, 2023 - ui.adsabs.harvard.edu
Immune checkpoint inhibitor treatment has the potential to prolong survival in non-small cell
lung cancer (NSCLC), however, some of the patients develop resistance following initial�…
lung cancer (NSCLC), however, some of the patients develop resistance following initial�…
Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with immunosuppressive T cell phenotype.
S Hiltbrunner, L Cords, S Kasser…�- Nature�…, 2023 - europepmc.org
Immune checkpoint inhibitor treatment has the potential to prolong survival in non-small cell
lung cancer (NSCLC), however, some of the patients develop resistance following initial�…
lung cancer (NSCLC), however, some of the patients develop resistance following initial�…
Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with immunosuppressive T cell phenotype
S Hiltbrunner, L Cords, S Kasser…�- Nature�…, 2023 - econpapers.repec.org
Immune checkpoint inhibitor treatment has the potential to prolong survival in non-small cell
lung cancer (NSCLC), however, some of the patients develop resistance following initial�…
lung cancer (NSCLC), however, some of the patients develop resistance following initial�…
Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with immunosuppressive T cell phenotype
S Hiltbrunner, L Cords, S Kasser…�- Nature�…, 2023 - pubmed.ncbi.nlm.nih.gov
Immune checkpoint inhibitor treatment has the potential to prolong survival in non-small cell
lung cancer (NSCLC), however, some of the patients develop resistance following initial�…
lung cancer (NSCLC), however, some of the patients develop resistance following initial�…
Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with immunosuppressive T cell phenotype
S Hiltbrunner, L Cords, S Kasser…�- Nature�…, 2023 - ideas.repec.org
Immune checkpoint inhibitor treatment has the potential to prolong survival in non-small cell
lung cancer (NSCLC), however, some of the patients develop resistance following initial�…
lung cancer (NSCLC), however, some of the patients develop resistance following initial�…
Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with immunosuppressive T cell phenotype.
S Hiltbrunner, L Cords, S Kasser…�- Nature�…, 2023 - search.ebscohost.com
Immune checkpoint inhibitor treatment has the potential to prolong survival in non-small cell
lung cancer (NSCLC), however, some of the patients develop resistance following initial�…
lung cancer (NSCLC), however, some of the patients develop resistance following initial�…